Filtered By:
Specialty: Cardiology
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 800 results found since Jan 2013.
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Cancers (Basel). 2023 Feb 22;15(5):1397. doi: 10.3390/cancers15051397.ABSTRACTCancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in m...
Source: Atherosclerosis - March 11, 2023 Category: Cardiology Authors: Vincenzo Quagliariello Irma Bisceglia Massimiliano Berretta Martina Iovine Maria Laura Canale Carlo Maurea Vienna Giordano Andrea Paccone Alessandro Inno Nicola Maurea Source Type: research
Blockade of CD47 function attenuates restenosis by promoting smooth muscle cell efferocytosis and inhibiting their migration and proliferation
J Biol Chem. 2023 Mar 8:104594. doi: 10.1016/j.jbc.2023.104594. Online ahead of print.ABSTRACTCluster of differentiation 47 (CD47) plays an important role in the pathophysiology of various diseases including atherosclerosis, but its role in neointimal hyperplasia which contributes to restenosis, has not been studied. Using molecular approaches in combination with a mouse vascular endothelial denudation model, we studied the role of CD47 in injury-induced neointimal hyperplasia. We determined that thrombin induced CD47 expression both in human and mouse aortic smooth muscle cells (HASMCs and MASMCs). In exploring the mechan...
Source: Atherosclerosis - March 10, 2023 Category: Cardiology Authors: Suresh Govatati Prahalathan Pichavaram Raj Kumar Gadiparthi N Rao Source Type: research
Dopamine D1 receptor activation ameliorates ox-LDL-induced endothelial cell senescence via CREB/Nrf2 pathway
Exp Cell Res. 2023 Mar 7:113542. doi: 10.1016/j.yexcr.2023.113542. Online ahead of print.ABSTRACTEndothelial cell senescence is involved in endothelial dysfunction and aging-related vascular diseases. The D1-like dopamine receptor (DR1), a number of G-protein-coupled receptors, is currently under consideration as a potential therapeutic target for the prevention of atherosclerosis. However, the role of DR1 in regulating ox-LDL-stimulated endothelial cell senescence remains unknown. Here, we found that the elevated Prx hyperoxidation and reactive oxygen species (ROS) levels in ox-LDL-treated Human umbilical vein endothelial...
Source: Atherosclerosis - March 9, 2023 Category: Cardiology Authors: Yiming Zhao Yuxia Li Hongxia Li Sa Shi Source Type: research
Pharmacological Inhibition of P-Rex1/Rac1 Axis Blocked Angiotensin II-Induced Cardiac Fibrosis
ConclusionOur findings demonstrated for the first time that P-Rex1 was an essential signaling mediator in CFs activation and subsequent cardiac fibrosis, and 1A-116 could be a potential pharmacological development drug.
Source: Cardiovascular Drugs and Therapy - March 9, 2023 Category: Cardiology Source Type: research
Inclisiran: A Review in Hypercholesterolemia
AbstractInclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA (siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby decreasing circulating low-density lipoprotein cholesterol (LDL-C). In the EU, inclisiran is indicated in adults with primary hypercholesterolemia or mixed dyslipidemia, as an adjunct to diet. It is intended for use in patients unable to reach LDL-C goals on maximally tolerated statin therapy, with or without other lipid-lowering therapies (LLTs). In patients who are statin intolerant or for whom a statin is contraindi...
Source: American Journal of Cardiovascular Drugs - March 4, 2023 Category: Cardiology Source Type: research
Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Pharmaceutics. 2023 Jan 18;15(2):323. doi: 10.3390/pharmaceutics15020323.ABSTRACTDyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis of lipid-lowering therapy. Nevertheless, these drugs are often insufficient due to their side effects and restrictive criteria for achieving the recommended LDL-C values. Even the addition of other drugs, i.e., ezetimibe, does not help one achieve th...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Łukasz Wołowiec Joanna Osiak Anna Wo łowiec Aleksandra Wijata El żbieta Grześk Mariusz Kozakiewicz Joanna Banach Alicja Nowaczyk Jacek Nowaczyk Grzegorz Grze śk Source Type: research
EVA1A (Eva-1 Homolog A) Promotes Endothelial Apoptosis and Inflammatory Activation Under Disturbed Flow Via Regulation of Autophagy
CONCLUSIONS: We identified EVA1A as a novel flow-sensitive gene that mediates the effects of proatherogenic DF on EC dysfunction by regulating autophagy.PMID:36794585 | DOI:10.1161/ATVBAHA.122.318110
Source: Arteriosclerosis, Thrombosis and Vascular Biology - February 16, 2023 Category: Cardiology Authors: Lindsay Canham Sam Sendac Mannekomba R Diagbouga Elena Wolodimeroff Daniela Pirri Blanca Tardajos Ayllon Shuang Feng Celine Souilhol Timothy J A Chico Paul C Evans Jovana Serbanovic-Canic Source Type: research
